Combining Cancer Immunotherapies

Targeted therapies act by blocking essential biochemical pathways or mutant proteins that are required for tumor cell growth and survival. These drugs can arrest tumor progression and induce striking regressions in molecularly defined subsets of patients. Indeed, the first small molecule targeted agent, the BCR-ABL kinase inhibitor imatinib, rapidly induced complete cytogenetic responses in 76% of chronic myelogenous leukemia patients. Further research into the underlying genetic pathways driving tumor proliferation uncovered additional oncoproteins that are critical for tumor maintenance, such as the epidermal growth factor receptor (EGFR), BRAF, KIT, HER (also known as neu and ERBB) and anaplastic lymphoma kinase (ALK). Similar to imatinib, small molecule inhibitors of these kinases have effectuated impressive tumor responses in selected patients, although regressions are commonly followed by the development of progressive disease due to the emergence of drug-resistant variants. Resistance usually involves secondary mutations within the targeted protein or compensatory changes within the targeted pathway that bypass the drug-mediated inhibition. Accordingly, targeted therapies may elicit dramatic tumor regressions, but persistence is generally short-lived, limiting the overall clinical benefit.

  • Targeted therapies
  • Rationale for immunotherapy
  • Combining radiotherapy
  • Standard therapies
  • Androgen manipulation
  • T-cell modulation
  • Inter-Leukeins
  • Interferons
  • T- cell growth
  • Cell Proliferation

Related Conference of Combining Cancer Immunotherapies

September 13-14, 2018

11th Annual Congress on Immunology & Immunotechnology

Zurich, Switzerland
September 17-18, 2018

3rd International Conference on Tumor & Cancer Immunology and Immunotherapy

San Diego, California, USA
September 17-18, 2018

3rd International Conference on Tumor & Cancer Immunology and Immunotherapy

San Diego, California, USA
September 20-21, 2018

Global Meet on Immunology and Molecular Biology

Oslo, Norway
October 19-20, 2018

10th World Congress and Expo on Immunology

New York, USA
October 29-30, 2018

6th International Conference on HIV/AIDS, STDs and STIs

San Francisco, USA
November 22-23, 2018

World Conference on Vaccine and Immunology

Bucharest, Romania
November 26-27, 2018

3rd International Conference on Autoimmunity

Dublin, Ireland
December 06-08, 2018

Annual Congress and Expo on Antibiotics

Amsterdam, Netherlands
March 04-05, 2019

10th Molecular Immunology & Immunogenetics Congress

Barcelona, Spain
March 18-19, 2019

11th Global Summit on Immunology and Cell Biology

Sydney, Australia
June 13-14, 2019 |

10th European Immunology Conference

Berlin, Germany

Combining Cancer Immunotherapies Conference Speakers

Recommended Sessions

Related Journals

Are you interested in